Background: BRCA1-mutated ovarian cancer poses substantial therapeutic hurdles due to its poor prognosis and resistance to traditional therapies. Although acquired resistance is still a significant obstacle, PARP inhibitors, e.g.... ...

请注册登录后继续浏览